Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
Franck Morschhauser(Hôpital Claude Huriez), Paula Marlton(Princess Alexandra Hospital), Umberto Vitolo(Azienda Ospedaliero Universitaria San Giovanni Battista), O. Lindén(Lund University), John F. Seymour(The University of Melbourne), Michael Crump(Princess Margaret Cancer Centre), Bertrand Coiffier(Hôpital Lyon Sud), Roberto Foà(Sapienza University of Rome), Elisabeth Wassner(Roche (Switzerland)), Hans Ulrich Burger(Roche (Switzerland)), Barbara J. Brennan(Roche (Switzerland)), Myriam Mendila(Roche (Switzerland))
Cited by 143
Abstract
Related Papers
No related papers found
Powered by citation graph analysis